SG11201407765VA - Aprepitant injectable formulations - Google Patents
Aprepitant injectable formulationsInfo
- Publication number
- SG11201407765VA SG11201407765VA SG11201407765VA SG11201407765VA SG11201407765VA SG 11201407765V A SG11201407765V A SG 11201407765VA SG 11201407765V A SG11201407765V A SG 11201407765VA SG 11201407765V A SG11201407765V A SG 11201407765VA SG 11201407765V A SG11201407765V A SG 11201407765VA
- Authority
- SG
- Singapore
- Prior art keywords
- aprepitant
- injectable formulations
- injectable
- formulations
- aprepitant injectable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Otolaryngology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hospice & Palliative Care (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261651501P | 2012-05-24 | 2012-05-24 | |
| US201361798276P | 2013-03-15 | 2013-03-15 | |
| PCT/US2013/042618 WO2013177501A2 (en) | 2012-05-24 | 2013-05-24 | Aprepitant injectable formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201407765VA true SG11201407765VA (en) | 2015-01-29 |
Family
ID=49622077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201407765VA SG11201407765VA (en) | 2012-05-24 | 2013-05-24 | Aprepitant injectable formulations |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20130317016A1 (en) |
| EP (1) | EP2855436A4 (en) |
| JP (1) | JP2015521190A (en) |
| KR (1) | KR20150022839A (en) |
| CN (1) | CN104619312A (en) |
| AU (1) | AU2013266141B2 (en) |
| BR (1) | BR112014029176A2 (en) |
| CA (1) | CA2874700A1 (en) |
| HK (1) | HK1203193A1 (en) |
| IL (1) | IL235864A0 (en) |
| MX (1) | MX2014014173A (en) |
| NZ (1) | NZ702114A (en) |
| RU (1) | RU2014147365A (en) |
| SG (1) | SG11201407765VA (en) |
| WO (1) | WO2013177501A2 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3054980B1 (en) * | 2013-10-08 | 2019-09-04 | InnoPharma, Inc. | Aprepitant oral liquid formulations |
| US20170290774A1 (en) * | 2014-07-24 | 2017-10-12 | Plus Vitech, S.L. | Neurokinin-1 receptor antagonist composition for treatment of diseases and conditions of the respiratory tract |
| US9808465B2 (en) | 2014-09-19 | 2017-11-07 | Heron Therapeutics, Inc. | Emulsion formulations of aprepitant |
| TWI586379B (en) | 2015-06-29 | 2017-06-11 | 永信藥品工業股份有限公司 | Method of preparing very slightly soluble drug with solid dosage form |
| US9913853B2 (en) | 2015-11-03 | 2018-03-13 | Cipla Limited | Stabilized liquid fosaprepitant formulations |
| US9974742B2 (en) | 2016-02-01 | 2018-05-22 | Heron Therapeutics, Inc. | Emulsion formulations of an NK-1 receptor antagonist and uses thereof |
| CN108883058A (en) * | 2016-02-01 | 2018-11-23 | 赫伦治疗有限公司 | Emulsion containing nk 1 receptor antagonist |
| EP3493815B1 (en) * | 2016-08-03 | 2022-02-16 | Zhuhai Beihai Biotech Co., Ltd. | Formulations of fosaprepitant and aprepitant |
| US11065265B2 (en) | 2018-05-18 | 2021-07-20 | Spes Pharmaceuticals Inc. | Compositions of fosaprepitant and methods of preparation |
| CN112168788B (en) * | 2019-07-01 | 2022-07-19 | 中国医学科学院药物研究所 | Aprepitant micelle sterile freeze-dried preparation for intravenous injection and preparation method thereof |
| CN112190546A (en) * | 2019-07-08 | 2021-01-08 | 苏州海特比奥生物技术有限公司 | Preparation method of aprepitant preparation |
| JP6832468B1 (en) * | 2020-07-15 | 2021-02-24 | キユーピー株式会社 | Emulsions, injections, and methods of preparing emulsions |
| CN113712915A (en) * | 2021-01-07 | 2021-11-30 | 广州曼翔医药有限公司 | Preparation method of aprepitant emulsion injection |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06006710A (en) * | 2003-12-17 | 2006-08-31 | Bionumerik Pharmaceuticals Inc | Pharmaceutical formulations of camptothecins and process for making same. |
| CA2597956C (en) * | 2005-02-17 | 2013-07-09 | Velcera Pharmaceuticals | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
| EP1942734A4 (en) * | 2005-10-06 | 2010-04-07 | Reddys Lab Ltd Dr | Preparation of aprepitant |
| US9227958B2 (en) | 2006-02-03 | 2016-01-05 | Glenmark Pharmaceuticals Limited | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof |
| EP2001481A4 (en) | 2006-03-29 | 2009-08-26 | Reddys Lab Ltd Dr | Aprepitant polymorph mixtures |
| EP2034952A4 (en) * | 2006-06-16 | 2011-08-17 | Reddys Lab Ltd Dr | Aprepitant compositions |
| JP5523829B2 (en) | 2006-06-29 | 2014-06-18 | アステックス、セラピューティックス、リミテッド | Compound drug |
| EP2129671A2 (en) | 2007-02-27 | 2009-12-09 | Sandoz AG | Novel polymorphs of aprepitant and processes for preparation |
| US20100151035A1 (en) | 2007-03-13 | 2010-06-17 | Sandoz Ag | Pharmaceutical compositions of poorly soluble drugs |
| US20110009362A1 (en) * | 2008-02-27 | 2011-01-13 | Dr. Reddy's Laboratories Ltd. | Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof |
| WO2010140132A1 (en) | 2009-06-02 | 2010-12-09 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline aprepitant having form i content |
| HUP1000325A2 (en) * | 2010-06-18 | 2012-01-30 | Druggability Technologies Ip Holdco Jersey Ltd | Nanostructured aprepitant compositions and process for their preparation |
| US9364518B2 (en) * | 2010-06-24 | 2016-06-14 | Torrent Pharmaceuticals Limited | Pharmaceutical composition containing goserelin for in-situ implant |
| CN102379845A (en) * | 2011-11-03 | 2012-03-21 | 南京优科生物医药有限公司 | Aprepitant microemulsion for injection and preparation method thereof |
-
2013
- 2013-05-24 CA CA2874700A patent/CA2874700A1/en not_active Abandoned
- 2013-05-24 CN CN201380027152.4A patent/CN104619312A/en active Pending
- 2013-05-24 US US13/901,978 patent/US20130317016A1/en not_active Abandoned
- 2013-05-24 MX MX2014014173A patent/MX2014014173A/en unknown
- 2013-05-24 RU RU2014147365A patent/RU2014147365A/en not_active Application Discontinuation
- 2013-05-24 WO PCT/US2013/042618 patent/WO2013177501A2/en active Application Filing
- 2013-05-24 BR BR112014029176A patent/BR112014029176A2/en not_active IP Right Cessation
- 2013-05-24 JP JP2015514214A patent/JP2015521190A/en active Pending
- 2013-05-24 KR KR20147035458A patent/KR20150022839A/en not_active Application Discontinuation
- 2013-05-24 EP EP13793678.7A patent/EP2855436A4/en not_active Withdrawn
- 2013-05-24 AU AU2013266141A patent/AU2013266141B2/en not_active Ceased
- 2013-05-24 SG SG11201407765VA patent/SG11201407765VA/en unknown
- 2013-05-24 NZ NZ702114A patent/NZ702114A/en not_active IP Right Cessation
-
2014
- 2014-11-23 IL IL235864A patent/IL235864A0/en unknown
-
2015
- 2015-04-15 HK HK15103668.8A patent/HK1203193A1/en unknown
-
2017
- 2017-01-30 US US15/419,191 patent/US9968614B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013177501A3 (en) | 2014-01-30 |
| AU2013266141B2 (en) | 2015-10-01 |
| CN104619312A (en) | 2015-05-13 |
| US20170136027A1 (en) | 2017-05-18 |
| EP2855436A4 (en) | 2016-01-06 |
| JP2015521190A (en) | 2015-07-27 |
| NZ702114A (en) | 2016-02-26 |
| BR112014029176A2 (en) | 2017-06-27 |
| IL235864A0 (en) | 2015-02-01 |
| KR20150022839A (en) | 2015-03-04 |
| CA2874700A1 (en) | 2013-11-28 |
| WO2013177501A2 (en) | 2013-11-28 |
| WO2013177501A4 (en) | 2014-03-20 |
| US9968614B2 (en) | 2018-05-15 |
| HK1203193A1 (en) | 2015-10-23 |
| EP2855436A2 (en) | 2015-04-08 |
| RU2014147365A (en) | 2016-07-20 |
| AU2013266141A1 (en) | 2014-12-11 |
| MX2014014173A (en) | 2015-07-21 |
| US20130317016A1 (en) | 2013-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1257028A1 (en) | Injectable preparation | |
| HK1203193A1 (en) | Aprepitant injectable formulations | |
| HK1212906A1 (en) | Vaccine compositions | |
| PL2647387T3 (en) | Vaccine Composition | |
| HRP20190841T1 (en) | Injectable formulation | |
| HK1215165A1 (en) | Compositions | |
| HK1204551A1 (en) | Injectable compositions | |
| EP2804611A4 (en) | Chitosan-derived compositions | |
| GB201201287D0 (en) | Compositions | |
| EP2887953A4 (en) | Improved daptomycin injectable formulation | |
| GB201318407D0 (en) | Compositions | |
| EP2926813A4 (en) | Metformin-orlistat compositions | |
| GB201209187D0 (en) | Compositions | |
| GB201204103D0 (en) | Compositions | |
| GB201204102D0 (en) | Compositions | |
| GB201203084D0 (en) | Compositions | |
| GB201203083D0 (en) | Compositions | |
| GB201203082D0 (en) | Compositions |